IMS Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

IMS Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-50	Closed	-$8K	–	316
2018 Q3	$8K	Buy	+50	New	+$6.83K	0.01%	333
2016 Q4	–	Sell	-5,132	Closed	-$315K	–	150
2016 Q3	$315K	Buy	+5,132	New	+$155K	0.36%	88
2016 Q1	–	Sell	-5,575	Closed	-$215K	–	128
2015 Q4	$215K	Sell	5,575 -1,132	-17%	-$36.7K	0.27%	104
2015 Q3	$215K	Sell	6,707 -12,900	-66%	-$438K	0.26%	108
2015 Q2	$597K	Buy	+19,607	New	+$401K	0.71%	51
2015 Q1	–	Sell	-41,175	Closed	-$596K	–	162
2014 Q4	$596K	Buy	41,175 +1,300	+3%	+$22K	0.68%	58
2014 Q3	$841K	Buy	39,875 +17,800	+81%	+$402K	0.98%	29
2014 Q2	$658K	Sell	22,075 -10,140	-31%	-$321K	0.72%	57
2014 Q1	$774K	Sell	32,215 -5,785	-15%	-$147K	0.91%	43
2013 Q4	$774K	Buy	+38,000	New	+$1.13M	0.97%	40

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IMS Capital Management's SRPT Position: Q4 2018 in Review

IMS Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 50 shares — an estimated $8K sold.

IMS Capital Management first reported a position in SRPT in Q4 2013 and held it in 10 quarters. The position peaked at $841K in Q3 2014. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

IMS Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
IMS Capital Management sold 50 Sarepta Therapeutics shares in Q4 2018, an estimated $8K.
IMS Capital Management first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 10 quarters.
IMS Capital Management's Sarepta Therapeutics position peaked at $841K in Q3 2014.
335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on IMS Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.